Perrigo Co. PLC, a pharmaceutical company, has agreed to buy Héra SAS for 1.8 billion euros, or roughly $2.1 billion, in a merger that would help cement Perrigo’s shift to focus on nonprescription drugs.
The all-cash acquisition of Héra would extend Dublin-based Perrigo’s presence in sales of blister-care, scar-care and women’s-health products. Héra, now co-owned by Astorg Partners, a private-equity firm, and by Goldman Sachs Asset Management, sells skin treatments such as Compeed and Mederma. It also makes ellaOne, an emergency contraceptive.
